When Cancer Vaccines Go Viral

Abstract

Induction of antitumor responses by vaccines requires strong immunogens. Heterologous viral prime/boost immunization with the BN-CV301 vaccine promotes activation of immune responses that provide a clinical benefit to patients with cancer. This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies.

CITA DEL ARTÍCULO  Clin Cancer Res. 2019 Aug 15;25(16):4871-4873. https://doi.org/10.1158/1078-0432.ccr-19-1652https://doi.org/10.1158/1078-0432.ccr-19-1652. Epub 2019 Jun 21.